BioPharma Resources

NDA 021908 · Sucampo Pharma LLC

Amitiza

Lubiprostone · Oral · Chloride Channel Activator

Novel

Last checked: Nov 19, 2026Latest source record: Nov 30, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Jan 31, 2006

Approved uses

4

Original approval plus efficacy supplements

Registered trials

51

24 Phase 3, 2 recruiting

FAERS reports

9,556

6,379 serious, 972 with death reported

AI brief across all sources

Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 28, 2026.

Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 ) Limitations of Use: Effectiveness of lubiprostone in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old. ( 1.3 ) 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 1.2 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain Lubiprostone is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. Limitations of Use: Effectiveness of Lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see Clinical Studies (14.2) ] 1.3 Irritable Bowel Syndrome with Constipation Lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in women at least 18 years old.

Mechanism: Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. Lubiprostone acts by specifically activating ClC-2, which is a normal constituent of the apical membrane of the human intestine, in a protein kinase A–independent fashion. By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with chronic idiopathic constipation. Patch clamp cell studies in human...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • AMITIZA · LUBIPROSTONE 24MCG · CAPSULE, ORAL · Prescription · TE AB
  • AMITIZA · LUBIPROSTONE 8MCG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lubiprostone" as an intervention, any sponsor and status, largest first.

All 51 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea803
  • dyspnoea641
  • diarrhoea633
  • constipation584
  • drug ineffective568
  • fatigue544
  • pain500
  • headache498
  • dizziness457
  • fall409
  • vomiting409
  • off label use350

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200618
200798
2008163
2009182
2010215
2011210
2012298
2013315
2014404
2015633
2016905
2017788
2018910
2019883
2020736
2021591
2022435
2023439
2024442
2025476
2026415

Recalls

3 FDA enforcement reports for this application.

  • May 13, 2019 · Class II · Terminated

    Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained...

  • May 13, 2019 · Class II · Terminated

    Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained...

  • Nov 6, 2018 · Class III · Terminated

    Failed Impurities/Degradation Specifications:Elevated levels of a known impurity in the 20-month stability sample testing.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Amitiza (Lubiprostone)

2024 spending

$2.9M

Beneficiaries

2,368

6,887 claims

Per beneficiary

$1,229

$5.65 per unit

View as table
YearSpending
2020$279,322,814
2021$89,363,650
2022$23,146,170
2023$8,420,705
2024$2,909,987

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 76 on PubMed

Sponsor: Sucampo Pharma LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.